Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients with Multiple Myeloma with Extramedullary Disease or Plasma Cell Leukemia by Buadi, Francis K., Lacy, Martha Q., Perez, Gabriela, Phuong-Dung, Liang, Kansagra, Ankit, Witzig, Thomas E., Helgeson, Dania Kaehlyn, Woolley, Karen, Auclair, Daniel, Cho, Hearn Jay, Kumar, Shaji K.

Get full text

Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma by Kumar, Shaji K., Kapoor, Prashant, Laplant, Betsy, Phuong-Dung, Liang, Muchtar, Eli, Buadi, Francis K., Gonsalves, Wilson I, Malave, Gabriella C, Vossen, Alanna M., Dingli, David, Go, Ronald S., Warsame, Rahma M, Kourelis, Taxiarchis, Hwa, Yi L., Fonder, Amie, Hobbs, Miriam A., Lust, John A., Lacy, Martha Q., Dispenzieri, Angela, Hayman, Suzanne R., Leung, Nelson, Rajkumar, S. Vincent, Gertz, Morie A.

Get full text